Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Erectile Dysfunction Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Erectile Dysfunction Overview | 11 | 1 |
| Pipeline Products for Erectile Dysfunction Comparative Analysis | 12 | 1 |
| Erectile Dysfunction Therapeutics under Development by Companies | 13 | 2 |
| Erectile Dysfunction Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Erectile Dysfunction Pipeline Products Glance | 16 | 4 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Unknown Stage Products | 19 | 1 |
| Erectile Dysfunction Products under Development by Companies | 20 | 2 |
| Erectile Dysfunction Products under Investigation by Universities/Institutes | 22 | 1 |
| Erectile Dysfunction Companies Involved in Therapeutics Development | 23 | 17 |
| Apricus Biosciences, Inc. | 23 | 1 |
| Aytu BioScience, Inc. | 24 | 1 |
| Biopharm GmbH | 25 | 1 |
| Futura Medical Plc | 26 | 1 |
| Hanmi Pharmaceuticals, Co. Ltd. | 27 | 1 |
| Humanetics Corporation | 28 | 1 |
| IntelGenx Corp. | 29 | 1 |
| Ion Channel Innovations, LLC | 30 | 1 |
| Mezzion Pharma Co. Ltd. | 31 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 32 | 1 |
| Monosol Rx, LLC | 33 | 1 |
| NAL Pharmaceuticals Ltd. | 34 | 1 |
| Palatin Technologies, Inc. | 35 | 1 |
| Pharmicell Co., Ltd. | 36 | 1 |
| Sihuan Pharmaceutical Holdings Group Ltd. | 37 | 1 |
| Suda Ltd | 38 | 1 |
| Yungjin Pharm. Co., Ltd. | 39 | 1 |
| Erectile Dysfunction Therapeutics Assessment | 40 | 10 |
| Assessment by Monotherapy Products | 40 | 1 |
| Assessment by Combination Products | 41 | 1 |
| Assessment by Target | 42 | 2 |
| Assessment by Mechanism of Action | 44 | 2 |
| Assessment by Route of Administration | 46 | 2 |
| Assessment by Molecule Type | 48 | 2 |
| Drug Profiles | 50 | 43 |
| (PDE-5 Inhibitor + tramadol hydrochloride) Drug Profile | 50 | 1 |
| alprostadil Drug Profile | 51 | 6 |
| AP-102 Drug Profile | 57 | 1 |
| avanafil Drug Profile | 58 | 1 |
| BIO-300 Drug Profile | 59 | 3 |
| BL-214 Drug Profile | 62 | 1 |
| Cellgram-ED Drug Profile | 63 | 1 |
| fadanafil Drug Profile | 64 | 1 |
| HCP-1302 Drug Profile | 65 | 1 |
| HCP-1303 Drug Profile | 66 | 1 |
| MED-2002 Drug Profile | 67 | 2 |
| MED-2005 Drug Profile | 69 | 1 |
| Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction Drug Profile | 70 | 1 |
| pVAX-hSlo Drug Profile | 71 | 1 |
| Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease Drug Profile | 72 | 2 |
| sildenafil citrate Drug Profile | 74 | 1 |
| sildenafil citrate Drug Profile | 75 | 1 |
| sildenafil citrate Drug Profile | 76 | 1 |
| Small Molecule to Inhibit PDE5 for Erectile Dysfunction Drug Profile | 77 | 1 |
| SUD-003 Drug Profile | 78 | 2 |
| Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction Drug Profile | 80 | 1 |
| T-6932 Drug Profile | 81 | 1 |
| tadalafil Drug Profile | 82 | 1 |
| tadalafil Drug Profile | 83 | 1 |
| tadalafil Drug Profile | 84 | 1 |
| TF-0092 Drug Profile | 85 | 1 |
| TPN-729 Drug Profile | 86 | 1 |
| TR-399 Drug Profile | 87 | 1 |
| udenafil Drug Profile | 88 | 3 |
| VLFIA-330 Drug Profile | 91 | 1 |
| YBH-1603 Drug Profile | 92 | 1 |
| Erectile Dysfunction Dormant Projects | 93 | 4 |
| Erectile Dysfunction Discontinued Products | 97 | 1 |
| Erectile Dysfunction Product Development Milestones | 98 | 9 |
| Featured News &Press Releases | 98 | 1 |
| Mar 28, 2016: MonoSol Rx Successfully Completes Pre-IND Meeting with the FDA for PharmFilm Tadalafil | 98 | 1 |
| Nov 25, 2015: iX Biopharma Announces Success Of Pilot Bioavailability Study For Pheonix | 98 | 1 |
| Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity | 99 | 1 |
| Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting | 99 | 1 |
| Nov 03, 2014: Auxilium Pharmaceuticals To Present STENDRA Data At SMSNA Scientific Meeting | 100 | 1 |
| Sep 18, 2014: VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity | 100 | 1 |
| Jul 09, 2014: New Grant Enables Humanetics to Evaluate Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients | 101 | 1 |
| Apr 11, 2014: VIVUS To Present Clinical Data On Avanafil at European Association of Urology | 102 | 1 |
| Feb 24, 2014: IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm Tadalafil Product | 102 | 1 |
| Jan 21, 2014: VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (avanafil) | 102 | 1 |
| Aug 01, 2013: VIVUS Announces Commercial Supply Agreement With Sanofi to Produce Avanafil | 103 | 1 |
| Jun 26, 2013: Vivus Announces European Approval For Spedra For Treatment Of Erectile Dysfunction | 103 | 2 |
| Jun 19, 2013: Vivus Announces Positive Results From TA-501 Clinical Trial Of Stendra For Treatment Of Men With Erectile Dysfunction | 105 | 1 |
| Apr 25, 2013: Vivus Receives CHMP Positive Opinion For Spedra For Treatment Of Erectile Dysfunction In Adult Men | 106 | 1 |
| Jul 18, 2012: Zydus Urosciences Launches Udenafil For Treatment Of Erectile Dysfunction In India | 106 | 1 |
| Appendix | 107 | 2 |
| Methodology | 107 | 1 |
| Coverage | 107 | 1 |
| Secondary Research | 107 | 1 |
| Primary Research | 107 | 1 |
| Expert Panel Validation | 107 | 1 |
| Contact Us | 107 | 1 |
| Disclaimer | 108 | 1 |